Biosimilars
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
The Cost of Drug Shortages
16 September 2024
Across the globe, drug shortages are becoming increasingly common.
Drug shortages are on the rise – but what is their impact?
16 September 2024
In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for quantifying the cost of a shortage, and through three case studies provide illustrative estimates of these costs.
Drug Shortages: What are the causes, consequences and pathways to a solution?
5 September 2024
Across the globe, drug shortages are becoming increasingly common across a range of therapeutic areas. Earlier this year, OHE published a report looking at the Dynamics…
The Dynamics of Drug Shortages
9 January 2024
Drug shortages are an industry-wide problem. Numerous factors may be considered as contributing to drug shortages across the globe. In this report, we discuss the global issue of drug shortages, summarise the main reasons for shortages as presented in the literature and our quantitative analysis. Finally, we provide recommendations for policy makers.
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
The CRA Report has an underlying assumption that the EU is as globally competitive in generics and biosimilars as it is in innovative products. There is…
Biosimilar Competition: Lessons from Europe and Prospects for the US
2 December 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
Experts from the three UK HTA agencies, the MHRA, and academia discussed which HTA methods are most appropriate for biosimilars in specific situations. OHE convened a…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…